Landmark Research Studies
completed

The objective of the LAAOS III study was to determine if removing the left atrial appendage can reduce stroke and other complications on top of usual therapy.

Primary outcome was the first occurrence of ischemic stroke* or transient ischemic attack with positive neuroimaging or systemic arterial embolism over the duration of follow-up.

Secondary outcomes over the duration of follow-up (unless otherwise specified) were:

1) All cause stroke or transient ischemic attack with positive neuroimaging or systemic arterial embolism.

2) Composite of ischemic stroke* or transient ischemic attack with positive neuroimaging or systemic arterial embolism or death.

3) Ischemic stroke *or transient ischemic attack with positive neuroimaging or systemic arterial embolism occurring more than 30 days after surgery.

4) All cause death.

Safety outcomes:

1) Hospitalization for heart failure.

2) Operative safety outcomes.

a. Chest tube output in the first post-operative 24 hours.

b. Re-operation for bleeding within the first 48 hours post-surgery.

c. 30-day mortality.

3) Major bleed.

4) Myocardial infarction.

* Ischemic stroke is defined as any stroke that is not documented as primary hemorrhagic.

All components of composite outcomes will also be reported individually.

LAAOS III trial - ACC 21 (Download PDF) Surgical AF Ablation Evaluation sub-study- ESC 21 (PDF)
Study Type

Interventional - Procedure

Study Design

Randomized, blinded, multicenter

NO. of Countries

27

NO. of Sites

105

NO. of Participants

4811

Study Period

2012 - 2021

Sponsor

PHRI

Canadian Institutes of Health Research (CIHR)

Heart & Stroke Foundation

Hamilton Health Sciences

Canadian Stroke Prevention Intervention Network (C-SPIN)

McMaster Surgical Associates (MSA)

PHRI

VIDEO: PHRI Scientist Richard Whitlock discusses the LAAOS III trial at ACC 2021 with Michael Gibson, CTR.

VIDEO: Richard Whitlock discusses surgical AF ablation evaluation (a LAAOS III sub-study) with Radcliffe Cardio during European Society of Cardiology (ESC) Congress 2021.

Back To Top